HST GLOBAL SETS NEW STANDARDS IN THE TREATMENT OF STAGE !V

[Guest guest]

HST GLOBAL, INC. SETS NEW STANDARDS IN THE TREATMENT OF STAGE IV BREAST

CANCER!

HST Global, Inc., (HSTC:hst global inc com

HSTC 4.75, -0.75, -13.6%) announced today it is meeting with 72% efficacy in

pre-clinical treatment of Stage IV cancer in a test of 250 patients. The

highlight of the study is in stage IV breast cancer where they have met with 79%

efficacy with 58 patients over 2 1/2 years with its drug candidate Salicinium.

Howell, President & CEO of HST Global, Inc., stated, " We are

encouraged by these results and are looking forward to subjecting the study to

more

rigorous tests to support eventual commercialization. "

About the Study:

HST Global, Inc., currently has the rights to a pre-clinical outcome-based

study using the pre-clinical drug trade named " Salicinium " . This natural

substance, which is plant-derived, is both oral and a parenteral active

inhibitor of

certain fermenting enzyme dynamics in the cancer cells. Clinical studies

demonstrate that Salicinium alters malignant cell fermentation dynamics, blocks

cell division (mitosis), and causes fermenting cancer cells to lose their

ability

to withstand innate immune reactions.

Given parenterally, in the form of the Forsythe Immune Therapy #2, the I.V.

contains proprietary amounts of normal saline, magnesium chloride, vitamin B6,

vitamin B12, B complex, folic acid, vitamin C, L-Lysine, zinc, glutathione,

and the main ingredient " Salicinium " . The preparation is succussed at the time

of the patient's visit, and it is prepared in approximately a 1:170 dilution.

The purpose of the pre-clinical outcome-based study in Stage IV adult cancers

is to study efficacy and safety issues. All patients coming to the clinical

are given the following choices:

1. Conventional chemotherapy, either first, second or third line,

asappropriate to the patient's prior history;2. Conventional chemotherapy,

either

standard or low-dose fractioned,with Salicinium;3. Conventional dose or low-dose

fractioned chemotherapy withSalicinium and other complimentary products;4.

Salicinium along with other complementary therapies;5. Salicinium alone;6.

Insulin

potentiated therapy using standard chemotherapy withSalicinium; and7. Any of the

above plus hormonal therapies.This study was carried out from June of 2005

through March of 2008, with 250 Stage IV cancer patients under study.

The advantages of the pre-clinical study were to show efficacy and safety,

and freedom from adverse toxicities and adverse side-effects. The conclusion of

the study was that Salicinium is a novel, homeopathic, immune boosting therapy

that when used alone in breast cancer, isolated from other cancers, showed an

overall response rate of 79% at 33 months.

When Salicinium was used in combination with chemotherapy, the overall

response rate was 75%.

These results compared favorably with conventional chemotherapy alone which,

in five years in the allopathic literature from 2004, showed only a 2.1%

survival rate in the United States with any form of chemotherapy alone.

It is important to note that this product is compatible with other

complementary therapies, which vector in on the metabolism of the cancer cell in

a

different matter.

Also of great importance is the fact that there were no significant adverse

events in these 250 patients using Salicinium, even when used with low-dose

fractioned chemotherapy.

The pre-clinical outcome-based study is available for review, with all the

statistics outline, which demonstrates the above positive effects.

HST Global, Inc. makes no representation that the US Food and Drug

Administration or any other regulatory agency will allow this Investigational

New Drug

to be marketed. Furthermore, no claim is made that potential medicine discussed

herein is safe, effective, or approved by the Food and Drug Administration.

Additionally, data that demonstrates activity or effectiveness in animals or in

vitro tests do not necessarily mean the formula test compound; referenced

herein will be effective in humans. Safety and effectiveness in humans will have

to be demonstrated by means of adequate and well-controlled clinical studies

before the clinical significance of the formula test compound is known. Readers

should carefully review the risk factors described in filings the Company

files from time to time with the Securities and Exchange Commission.

About HST Global, Inc.

HST Global, Inc. is a development stage biotechnology company that acquires

and develops innovative products for the treatment of cancer. We focus on

in-licensing drug candidates that are undergoing or have already completed

initial

clinical testing for the treatment of cancer, and then developing those drug

candidates for commercial use.

HST Global, Inc. wishes to inform readers that forward-looking statements in

this release are made pursuant to the " safe harbor " provisions of the Private

Securities Litigation Reform Act of 1995. Readers are cautioned that such

forward looking statements involve risks and uncertainties including, without

limitation, unforeseen changes in the course of research and development

activities and in clinical trials by others; possible acquisitions of other

technologies, assets or businesses; possible actions by customers, suppliers,

competitors, regulatory authorities; and other risks detailed from time to time

in the

Company's periodic reports filed with the Securities and Exchange Commission.

SOURCE: HST Global, Inc.

HST Global, Inc.Investor RelationsWesley Tate, 757-766-6100ir@...

www.hstglobal.comCopyright Business Wire 2008

**************

Play online games for FREE at Games.com! All of your favorites,

no registration required and great graphics – check it out!

(http://pr.atwola.com/promoclk/100000075x1211202682x1200689022/aol?redir=

http://www.games.com?ncid=emlcntusgame00000001)